Puma Biotechnology Inc (NYSE:PBYI)‘s stock had its “outperform” rating reaffirmed by stock analysts at Cowen and Company in a research report issued to clients and investors on Saturday. They presently have a $120.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $91.00. Cowen and Company’s target price indicates a potential upside of 27.25% from the company’s previous close.

A number of other equities research analysts also recently issued reports on the stock. Bank of America Corporation reissued a “buy” rating and issued a $117.00 price target (up from $100.00) on shares of Puma Biotechnology in a report on Friday. Leerink Swann reissued an “outperform” rating and issued a $125.00 price target (up from $115.00) on shares of Puma Biotechnology in a report on Wednesday. Royal Bank Of Canada set a $88.00 price target on shares of Puma Biotechnology and gave the stock a “hold” rating in a report on Monday, July 17th. J P Morgan Chase & Co reissued a “buy” rating on shares of Puma Biotechnology in a report on Tuesday. Finally, Citigroup Inc. reissued a “buy” rating and issued a $114.00 price target on shares of Puma Biotechnology in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $101.75.

Puma Biotechnology (PBYI) traded down 0.47% during trading on Friday, reaching $94.30. 856,767 shares of the company’s stock traded hands. The company’s 50 day moving average is $84.95 and its 200-day moving average is $50.35. Puma Biotechnology has a 52-week low of $28.35 and a 52-week high of $97.15. The stock’s market cap is $3.49 billion.

Puma Biotechnology (NYSE:PBYI) last released its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.06) by $0.09. On average, analysts anticipate that Puma Biotechnology will post ($8.43) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/22/cowen-and-company-reaffirms-outperform-rating-for-puma-biotechnology-inc-nysepbyi.html.

In related news, SVP Richard Paul Bryce sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $87.10, for a total value of $435,500.00. Following the sale, the senior vice president now directly owns 34,237 shares of the company’s stock, valued at $2,982,042.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Adage Capital Partners Gp, L.L sold 1,235,700 shares of the firm’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $75.38, for a total transaction of $93,147,066.00. The disclosure for this sale can be found here. Insiders sold 1,995,088 shares of company stock worth $157,988,613 over the last ninety days. 22.70% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in the stock. Barclays PLC increased its stake in shares of Puma Biotechnology by 453.2% in the first quarter. Barclays PLC now owns 3,961 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 3,245 shares in the last quarter. Teacher Retirement System of Texas increased its stake in shares of Puma Biotechnology by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 3,848 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 465 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of Puma Biotechnology by 112.0% in the third quarter. BNP Paribas Arbitrage SA now owns 2,133 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 1,127 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Puma Biotechnology by 253.3% in the third quarter. Tower Research Capital LLC TRC now owns 2,427 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 1,740 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Puma Biotechnology during the second quarter worth $183,000. 80.98% of the stock is currently owned by institutional investors and hedge funds.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.